Prohibix provides injectable biotherapeutics using its HYALUTE™ microparticle platform, which forms a hyaluronic‑acid depot for sustained tissue lubrication, anti‑inflammatory action, and controlled drug release over weeks to months. The platform supports encapsulation of small molecules, peptides, or nucleic acids and is delivered via standard intramuscular or subcutaneous injection, targeting pharmaceutical partners and healthcare providers treating age‑related degenerative conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Age‑related tissue degeneration reduces functional capacity and increases chronic disease burden, yet existing therapeutics often require frequent dosing and lack localized, long‑acting effects.
Solution
Prohibix delivers injectable biotherapeutics built on its proprietary HYALUTE™ microparticle platform. The formulation creates a depot of hyaluronic‑acid‑based particles that continuously lubricate tissue, provide sustained anti‑inflammatory activity, and release therapeutic agents over weeks to months. By enabling controlled, localized delivery, the platform reduces dosing frequency and improves systemic exposure profiles for a range of age‑related indications. The technology is positioned for partnership with pharmaceutical companies and for direct supply to healthcare providers managing chronic and longevity‑focused treatments.
Target Audience
Primary customers are pharmaceutical partners developing age‑related therapies and healthcare providers treating chronic degenerative conditions that benefit from long‑acting injectable solutions.
Features
- HYALUTE™ microparticles composed of cross‑linked hyaluronic acid for biocompatibility and intrinsic tissue lubrication
- Controlled‑release matrix engineered to modulate drug elution kinetics from days to several months
- Integrated anti‑inflammatory payloads that act locally to attenuate cytokine‑mediated tissue damage
- Injectable formulation compatible with standard intramuscular or subcutaneous delivery devices
- Scalable GMP manufacturing process allowing consistent particle size distribution and batch‑to‑batch reproducibility
- Platform flexibility to encapsulate small molecules, peptides, or nucleic‑acid therapeutics without reformulating the carrier
- In‑vivo stability data demonstrating prolonged residence time and minimal systemic clearance of the carrier matrix